Profile data is unavailable for this security.
About the company
Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is focused on development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. It is focused on four core programs: Large B-Cell Lymphoma (LBCL), Chronic Lymphocytic Leukemia (CLL), Autoimmune Disease and Renal Cell Carcinoma. It is developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion and advanced proprietary T cell manufacturing technologies. Its product candidate, cemacabtagene ansegedleucel, referred to as cema-cel, is an engineered allogeneic CAR T cell product candidate that targets CD19, a protein expressed on the cell surface of B cells and a validated target for B cell driven hematological malignancies. It is focused on developing cema-cel for LBCL and CLL. Its pipeline also includes ALLO-316, ALLO-329 and ALLO-647.
- Revenue in USD (TTM)43.00k
- Net income in USD-283.43m
- Incorporated2017
- Employees232.00
- LocationAllogene Therapeutics Inc210 East Grand AvenueSOUTH SAN FRANCISCO 94080United StatesUSA
- Phone+1 (650) 457-2700
- Fax+1 (302) 636-5454
- Websitehttps://allogene.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4D Molecular Therapeutics Inc | 18.00k | -143.48m | 415.24m | 201.00 | -- | 0.7513 | -- | 23,068.72 | -2.76 | -2.76 | 0.0004 | 10.63 | 0.00004 | -- | -- | 122.45 | -29.72 | -32.67 | -31.26 | -34.90 | -- | -- | -797,111.10 | -617.15 | -- | -- | 0.00 | -- | 562.29 | 7.96 | 6.19 | -- | 46.26 | -- |
| Zenas Biopharma Inc | 0.00 | -128.97m | 415.43m | 115.00 | -- | 1.21 | -- | -- | -3.19 | -3.19 | 0.00 | 8.60 | 0.00 | -- | -- | 0.00 | -52.94 | -- | -60.31 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 68.88 | -- | -- | -- |
| Cartesian Therapeutics Inc | 47.94m | -244.83m | 422.40m | 38.00 | -- | 528.14 | -- | 8.81 | -37.79 | -37.79 | 3.25 | 0.0315 | 0.1708 | -- | 9.86 | 1,261,526.00 | -87.23 | -43.66 | -94.16 | -66.84 | -- | -- | -510.72 | -136.35 | -- | -0.3505 | 0.00 | -- | -76.53 | 95.83 | -721.02 | -- | -25.27 | -- |
| Foghorn Therapeutics Inc. | 25.52m | -91.22m | 429.18m | 116.00 | -- | -- | -- | 16.82 | -1.91 | -1.91 | 0.5133 | -0.5088 | 0.0821 | -- | -- | 219,956.90 | -29.34 | -31.35 | -35.57 | -35.69 | -- | -- | -357.53 | -777.33 | -- | -- | -- | -- | 77.63 | -- | 9.60 | -- | -4.50 | -- |
| ACELYRIN Inc | 0.00 | -264.41m | 432.17m | 130.00 | -- | 0.8192 | -- | -- | -2.68 | -2.68 | 0.00 | 5.29 | 0.00 | -- | -- | 0.00 | -37.27 | -- | -41.69 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -489.21 | -- | -- | -- |
| Allogene Therapeutics Inc | 43.00k | -283.43m | 442.41m | 232.00 | -- | 0.9532 | -- | 10,288.56 | -1.53 | -1.53 | 0.0002 | 2.21 | 0.00007 | -- | -- | 185.34 | -43.56 | -28.46 | -46.04 | -30.21 | -- | -- | -659,137.20 | -1,123.44 | -- | -- | 0.00 | -- | -39.10 | -- | 3.86 | -- | -14.06 | -- |
| Taysha Gene Therapies Inc | 9.92m | -22.77m | 446.78m | 52.00 | -- | 5.03 | -- | 45.06 | -0.0625 | -0.0625 | 0.0421 | 0.4333 | 0.0527 | -- | -- | 190,673.10 | -12.11 | -- | -27.40 | -- | -- | -- | -229.67 | -- | -- | -- | 0.328 | -- | 517.55 | -- | 32.80 | -- | -- | -- |
| Omeros Corp | 0.00 | -185.38m | 447.93m | 198.00 | -- | -- | -- | -- | -3.14 | -2.30 | 0.00 | -2.66 | 0.00 | -- | -- | 0.00 | -45.98 | -55.51 | -61.42 | -70.10 | -- | -- | -- | -- | -- | -6.07 | 1.59 | -- | -- | -- | 3.91 | -- | -5.56 | -- |
| Aura Biosciences Inc | 0.00 | -83.22m | 447.94m | 88.00 | -- | 2.57 | -- | -- | -1.73 | -1.73 | 0.00 | 3.51 | 0.00 | -- | -- | 0.00 | -43.22 | -- | -46.30 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -30.03 | -- | -- | -- |
| Olema Pharmaceuticals Inc | 0.00 | -122.68m | 450.69m | 87.00 | -- | 2.27 | -- | -- | -2.19 | -2.19 | 0.00 | 3.47 | 0.00 | -- | -- | 0.00 | -46.92 | -30.06 | -51.51 | -31.40 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 7.76 | -- | -- | -- |
| Y-mAbs Therapeutics Inc | 84.55m | -23.86m | 452.37m | 100.00 | -- | 4.89 | -- | 5.35 | -0.541 | -0.541 | 1.92 | 2.06 | 0.677 | 1.13 | 4.36 | 845,530.00 | -19.11 | -44.23 | -23.55 | -50.45 | 88.89 | -- | -28.22 | -181.13 | 3.54 | -- | 0.00 | -- | 29.96 | -- | 77.58 | -- | -- | -- |
| Regenxbio Inc | 84.33m | -238.81m | 454.82m | 344.00 | -- | 1.51 | -- | 5.39 | -5.03 | -5.03 | 1.76 | 6.09 | 0.1463 | -- | 3.27 | 245,136.60 | -41.43 | -16.75 | -51.75 | -19.08 | 54.36 | 78.27 | -283.19 | -72.06 | -- | -- | 0.00 | -- | -19.94 | -16.21 | 6.00 | -- | -5.59 | -- |
| OmniAB Inc | 20.41m | -63.02m | 454.93m | 106.00 | -- | 1.59 | -- | 22.29 | -0.6227 | -0.6227 | 0.2017 | 2.43 | 0.0564 | -- | 4.24 | 192,537.70 | -17.43 | -- | -18.43 | -- | -- | -- | -308.78 | -- | -- | -- | 0.00 | -- | -42.17 | -- | -126.65 | -- | -- | -- |
| MeiraGTx Holdings PLC | 13.93m | -88.18m | 456.93m | 389.00 | -- | 4.80 | -- | 32.80 | -1.30 | -1.30 | 0.2123 | 1.23 | 0.0492 | -- | 1.08 | 33,243.44 | -31.12 | -26.40 | -39.74 | -32.66 | -7.72 | -- | -633.05 | -420.70 | -- | -- | 0.4324 | -- | -11.95 | -- | 35.17 | -- | 12.37 | -- |
| Kalvista Pharmaceuticals Inc | 0.00 | -141.77m | 457.69m | 150.00 | -- | 2.32 | -- | -- | -3.54 | -3.54 | 0.00 | 4.01 | 0.00 | -- | -- | 0.00 | -78.65 | -40.63 | -87.52 | -43.67 | -- | -- | -- | -2,972.81 | -- | -- | 0.00 | -- | -- | -- | -36.31 | -- | -16.34 | -- |
| Arcturus Therapeutics Holdings Inc | 160.40m | -62.64m | 462.38m | 180.00 | -- | 1.77 | -- | 2.88 | -2.33 | -2.33 | 5.95 | 9.67 | 0.3873 | -- | 4.69 | 891,105.60 | -15.13 | -19.66 | -18.67 | -24.90 | -- | -- | -39.05 | -77.55 | -- | -- | 0.00 | -- | -19.03 | 60.31 | -417.95 | -- | 14.44 | -- |
Data as of Nov 22 2024. Currency figures normalised to Allogene Therapeutics Inc's reporting currency: US Dollar USD
42.34%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 30 Sep 2024 | 30.02m | 14.36% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 10.48m | 5.01% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 8.11m | 3.88% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 7.01m | 3.35% |
| Capital Research & Management Co. (World Investors)as of 30 Sep 2024 | 6.90m | 3.30% |
| Lynx1 Capital Management LPas of 30 Sep 2024 | 6.20m | 2.97% |
| PRIMECAP Management Co.as of 30 Sep 2024 | 5.67m | 2.71% |
| Citadel Advisors LLCas of 30 Sep 2024 | 5.03m | 2.41% |
| T. Rowe Price Associates, Inc. (IM)as of 30 Sep 2024 | 4.74m | 2.27% |
| Woodline Partners LPas of 30 Sep 2024 | 4.36m | 2.09% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
